Ian M. Waxman

TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.

TL;DR: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.

TL;DR: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.

TL;DR: Treatment-related AEs with nivolumab monotherapy were primarily low grade, and most resolved with established safety guidelines, and objective response rate (ORR) was significantly higher in patients who experienced treatment-related select AEs of any grade compared with those who did not.

TL;DR: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivorumab as a new standard of care across a broad range of patients with previously treated aRCC.